The METTL3 inhibitor STM2457 suppresses gastric cancer progression by modulating m6A RNA modification
PLOS One · 2026
DOI: 10.1371/journal.pone.0345744 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, 2026. Verfasst von Hang Sun und 13 weiteren Autor:innen. Beteiligte Einrichtung: Shandong Institute of Parasitic Diseases, Shandong First Medical University & Shandong Academy of Medical Sciences, Jining, Shandong, China. Hauptthemen laut MEDLINE: Stomach Neoplasms, Methyltransferases, Adenosine. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medicine and Health Science Technology Development Plan of Shandong Province, Natural Science Foundation of Shandong Province, key research and development plan of Jining.
Abstract (Originalsprache)
Gastric cancer (GC) is one of the most common and lethal cancers globally. methyltransferase-like 3 (METTL3)-mediated N6-methyladenosine (m 6 A) RNA methylation plays a crucial role in tumor initiation and progression by regulating RNA function. STM2457, a highly efficient METTL3 inhibitor, can inhibit METTL3 activity and may serve as a potential therapeutic strategy in cancers. However, the role of STM2457 for GC cells is still unknown. In this study, we analyzed the expression profile data of GC in TCGA and GEO databases, and further explored the expression involvement of METTL3 in GC cell line, investigated the therapeutic effect of STM2457 targeted inhibition of METTL3 in GC both in vitro and in vivo experiments. The results indicated that STM2457 could suppress GC cell proliferation and migration by inhibiting METTL3, and also promoted cell apoptosis and arrest the cell cycle in S phase. In addition, STM2457 could inhibit tumor growth in subcutaneous xenotransplantation mouse model. Our findings suggested that STM2457 had great potential for the treatment of GC and could serve as a foundation for future clinical applications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Shandong Institute of Parasitic Diseases, Shandong First Medical University & Shandong Academy of Medical Sciences, Jining, Shandong, China.
- Digestive Disease Hospital of Shandong First Medical University, Shandong First Medical University & Shandong Academy of Medical Sciences, Jining, Shandong, China.
- Instrumentation and Service Center for Science and Technology, Beijing Normal University, Zhuhai, Guangdong, China.
- Clinical Laboratory, Affiliated Hospital of Jining Medical University, Jining, Shandong, China.
ORCID-Profile: Kun Yin
Förderung
- Medicine and Health Science Technology Development Plan of Shandong Province
- Natural Science Foundation of Shandong Province
- key research and development plan of Jining
- Taishan Scholar Foundation of Shandong Province
Zitieren
APA
Sun, H., Xu, H., Li, J., Xie, X., Zhang, J., Dong, H., Xie, H., Wang, Q., Zhao, G., Yin, K., Yang, J., Zhou, J., Wu, R., & Xu, C. (2026). The METTL3 inhibitor STM2457 suppresses gastric cancer progression by modulating m6A RNA modification. PLOS One. https://doi.org/10.1371/journal.pone.0345744
Vancouver
Sun H, Xu H, Li J, Xie X, Zhang J, Dong H, et al. The METTL3 inhibitor STM2457 suppresses gastric cancer progression by modulating m6A RNA modification. PLOS One. 2026. doi:10.1371/journal.pone.0345744
BibTeX
@article{Sun2026,
author = {Sun, Hang and Xu, Haozhi and Li, Junying and Xie, Xiaoman and Zhang, Junmei and Dong, Hongjie and Xie, Huanhuan and Wang, Qi and Zhao, Guihua and Yin, Kun and Yang, Jingyu and Zhou, Jianwei and Wu, Ruili and Xu, Chao},
title = {The METTL3 inhibitor STM2457 suppresses gastric cancer progression by modulating m6A RNA modification},
journal = {PLOS One},
year = {2026},
doi = {10.1371/journal.pone.0345744}
}
EUVIMED